Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage.
Front Pharmacol
; 13: 926750, 2022.
Article
in En
| MEDLINE
| ID: mdl-35873586
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Pharmacol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: